GHIT Fund allocates JPY 140 million to develop a portable rapid‑diagnostic system for Ebola, aiming to bolster outbreak‑response readiness
Executive summary: GHIT Fund invested JPY 140 million in a collaborative project to build a portable rapid diagnostic system for Ebola, involving Osaka Metropolitan University, KK DNAFORM and INRB. The investment aims to produce a point‑of‑care test that can improve early detection and containment of Ebola outbreaks, addressing a persistent gap in global health preparedness.
Who is involved: GHIT Fund (investor), Osaka Metropolitan University (academic partner), K.K. DNAFORM (technology partner), INRB (Institut National de Recherche Biomédicale, Democratic Republic of the Congo).
Likely next: Project teams will proceed with prototype development, followed by laboratory validation and field trials in Ebola‑affected regions, with potential regulatory submissions to WHO for emergency use listing.
The Global Health Innovative Technology (GHIT) Fund announced an investment of approximately JPY 140 million (about USD 862,000) in a joint project involving Osaka Metropolitan University, K.K. DNAFORM and the Institut National de Recherche Biomédicale (INRB) to create a portable rapid diagnostic test for Ebola virus disease. The funding supports the development of a point‑of‑care device that could be deployed quickly in remote or resource‑limited settings during future outbreaks. While the amount is modest, the initiative reflects continued donor interest in strengthening global health security through diagnostic innovation.
Timeline
- — GHIT Fund Invests Approx. JPY 140 Million in a Portable Rapid Diagnostic System for Ebola Disease in a Joint Project Between Osaka Metropolitan University, K.K. DNAFORM, and INRB (PR Newswire)
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped